Description

Lixte Biotechnology Holdings, Inc. functions as a biopharmaceutical firm dedicated to the discovery and development of innovative therapeutic compounds. The company leverages advanced biomarker technology to create novel drug candidates aimed at combating severe and widespread human diseases. Its core research primarily concentrates on protein phosphatase inhibitors, which are being explored for standalone administration or in conjunction with cytotoxic agents, radiation therapy, and immune checkpoint blockers. The company's developmental pipeline includes two distinct series of pharmacologically active agents, both progressing through various preclinical and clinical phases. The LB-100 series comprises new chemical entities designed to address cancers, vascular ailments, and metabolic disorders. Meanwhile, the LB-200 series is being developed to treat chronic hereditary conditions, such as Gaucher's disease, alongside certain types of cancer and neurodegenerative illnesses. Lixte Biotechnology Holdings, Inc. maintains significant research collaborations, including a clinical trial agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. It also has partnership agreements for investigator-initiated clinical trials with the Spanish Sarcoma Group, as well as the Netherlands Cancer Institute and Oncode Institute. Established in 2005, the company's headquarters are located in Pasadena, California.